Oct 5, 2023
MediSieve's Innovative Technology Recognised at Dutch Anaesthesiology Association Event
MediSieve's Phase I collaborative work with Radboud Medical Centre was recognised at the Dutch Anaesthesiology Association event.
LONDON, October 5, 2023 – MediSieve is delighted to announce that its collaborative work with Nicole Waalders from Radboud Medical Center in the Netherlands has been recognised by the Dutch Anaesthesiology Association. Nicole Waalders was awarded the prestigious prize for the best abstract presentation, focusing on MediSieve’s cutting-edge magnetic haemofiltration technology, at this year's Dutch Anaesthesiology Association Science Day in Utrecht.
The event, which took place under the theme "Bloody Mess," served as a dynamic platform for professionals to discuss recent developments and insights in anaesthesiology. Nicole's presentation highlighted the revolutionary potential of MediSieve's technology in patient care and treatment, making it a standout at the event.
"We are thrilled to see Nicole Waalders receiving such a prestigious honour for her presentation on our collaborative work," stated Dr George Frodsham, CEO. "Her remarkable achievement is not only a testament to our technology's potential but also reflects our commitment to advancing patient care through innovation."
MediSieve's collaboration with Nicole Waalders and her team during the Phase I clinical studies last year was a significant milestone in the development of their magnetic haemofiltration technology. This recognition further solidifies MediSieve's position as a pioneer in the medical technology industry.
"Working alongside Nicole and her team at Radboudumc has been an incredible journey. This accolade is a clear indication of the impactful work we are doing together. As we continue our partnership, we remain focused on developing solutions that will revolutionise patient care and treatment in the medical field," added Dr Frodsham.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Capture System captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: